Skip to Content

Nepafenac ophthalmic Pregnancy and Breastfeeding Warnings

Nepafenac ophthalmic is also known as: Ilevro, Nevanac

Nepafenac ophthalmic Pregnancy Warnings

Use is not recommended.

US FDA pregnancy category: C

Comments:
-This drug should not be used by women of child bearing potential not using contraception.
-Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (premature closure of ductus arteriosus), the use of this drug during late pregnancy should be avoided.

Animal studies have shown reproductive toxicity. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Nepafenac ophthalmic Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.

References for breastfeeding information

  1. "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide